Contents

Abbott, M. E., see Dudek, B. C., et al. 46

Adam, K., Oswald, I., Shapiro, C.
Effects of loprazolam and of triazolam on sleep and overnight urinary cortisol 389

Adam, K., see Morgan, K., et al. 386

Ahlskog, J. E., Randall, P. K., Hernandez, L., Hoebel, B. G.
Diminished amphetamine anorexia and enhanced fenfluramine anorexia after midbrain 6-hydroxydopamine 118

Alexander, P., see Kucharski, L. T., et al. 194

Anderson, G. M., see Shaywitz, B. A., et al. 73

Announcement 411

Appel, J. B., see Nielsen, E. B., et al. 233

Archer, T., Ögren, S.-O., Ross, S. B., Magnusson, O.
Retention deficits induced by acute *p*-chloroamphetamine following fear conditioning in the rat 14

Bajusz, S., see Székely, J. I., et al. 400

Balsara, J. J., Nandal, N. V., Burte, N. P., Jadhav, J. H., Chandorkar, A. G.
Effects of naloxone on methamphetamine and apomorphine stereotypy and on haloperidol catalepsy in rats 237

Baratti, C. M., see Introini, I. B., et al. 107

Barnes, T. R. E., see Braude, W. M., et al. 95

Benton, D., Dalrymple-Alford, J. C., McAllister, K. H., Brain, P. F., Brain, S.
Comparison in the mouse of the effect of the opiate delta receptor antagonist ICI 154 129 and naloxone in tests of extinction, passive avoidance and food intake 41

Bennett, J. A., Hirschowitz, J., Zemlan, F., Niven Thurman, D., Garver, D. L.
Combined thioridazine and desipramine: early antidepressant response 263

Berge, O.-G., see Fasmer, O. B., et al. 306

Bergmann, F., Cohen, E., Lieblich, I.
Biphasic effects of chronic saccharin intake on pain responses of healthy and diabetic rats of two genetically selected strains 248

Bihari, K., see Fekete, M., et al. 93

Bird, K. D., see Christie, M. J., et al. 378

Bjørndal, N., see Gerlach, J., et al. 131

Boe, I. N., see Carroll, M. E. 151

Boeck, V., Jørgensen, A., Fredricson Overø, K.
Comparative animal studies on cardiovascular toxicity of tri- and tetracyclic antidepressants and citalopram; relation to drug plasma levels 275

Bolwig, T. G., see Clemmesen, L., et al. 348

Borrell, S., see Guaza, C. 181

Bradley, C. M., Nicholson, A. N.
Flurazepam hydrochloride and its principal metabolites: Behavioural studies in the monkey *(Macaca mulatta)* 395

Brain, P. F., see Benton, D., et al. 41

Brain, S., see Benton, D., et al. 41

Branconnier, R. J., Harto-Truax, N. E., Cole, J. O.
The effect of aging on the positive chronotropic response to amitriptyline 256

Braude, W. M., Charles, I. P., Barnes, T. R. E.
Coarse, jerky foot tremor: Tremographic investigation of an objective sign of acute akathisia 95

Bunney, W. C., Massari, V. J., Pert, A.
Chronic morphine-induced hyperactivity in rats is altered by nucleus accumbens and ventral tegmental lesions 318

Burte, N. P., see Balsara, J. J., et al. 237

Cadow, B., see White, K., et al. 258

Campbell, I. C., see Durcan, M. J., et al. 215

Carey, R. J., DeVeaugh-Geiss, J.
Treatment schedule as a determinant of the development of tolerance to haloperidol 164

Carr, G. D., White, N. M.
The relationship between stereotypy and memory improvement produced by amphetamine 203

Carroll, M. E., Boe, I. N.
Effect of dose on increased etonitazene self-administration by rats due to food deprivation 151

Cavagnini, F., Maraschini, C., Dubini, A., Ramella, G., Danesi, L., Fossati, R.
Inhibition by phospholipid liposomes of the prolactin and cortisol response to insulin hypoglycemia in man 157

Chait, L. D., Uhlenhuth, E. H., Johanson, C. E.
An experimental paradigm for studying the discriminative stimulus properties of drugs in humans 272

Chait, L. D., see Henningfield, J. E., et al. 1

Chandorkar, A. G., see Balsara, J. J., et al. 237

Charles, I. P., see Braude, W. M., et al. 95

Cherek, D. R., see Dworkin, S. I., et al. 282

Chesher, G. B., see Christie, M. J., et al. 378

Christensson, E., see Gerlach, J., et al. 131

Christie, M. J., Chesher, G. B., Bird, K. D.
No evidence for a protracted change in endogenous opioid activity following chronic opiate treatment in mice: parallel recovery of cross tolerance to stress and morphine antinociception 378

Clemmesen, L., Mikkelsen, P. L., Lund, H., Bolwig, T. G., Rafaelsen, O. J.
Assessment of the anticholinergic effects of antidepressants in a single-dose cross-over study of salivation and plasma levels 348

Cohen, E., see Bergmann, F., et al. 248

Cohen, D. J., see Shaywitz, B. A., et al. 73

Cole, J. O., see Branconnier, R. J., et al. 256

Collins, R. J., Weeks, J. R., Cooper, M. M., Good, P. I., Russell, R. R.
Prediction of abuse liability of drugs using IV self-administration by rats 6

Consolo, S., see Garattini, S., et al. 210

Cooper, M. M., see Collins, R. J., et al. 6

Costall, B., Domeney, A. M., Naylor, R. J.
Locomotor hyperactivity caused by dopamine infusion into the nucleus accumbens of rat brain: specificity of action 174

Coyle, J., see Kucharski, L. T., et al. 194

Coyle, J. T., see Sanberg, P. R., et al. 406

Crocker, A. D., Overstreet, D. H.
Modification of the behavioural effects of haloperidol and of dopamine receptor regulation by altered thyroid status 102

Curzon, G., see Tricklebank, M. D., et al. 185

Dalrymple-Alford, J. C., see Benton, D., et al. 41

Damjanov, I., see Giknis, M. L. A. 229

Danesi, L., see Cavagnini, F., et al. 157

David, M. B., see Weizman, A., et al. 382

DeVeaugh-Geiss, see Carey, R. J. 164

Deviche, P., Schepers, G.
Naloxone treatment attenuates food but not water intake in domestic pigeons 122

Domeney, A. M., see Costall, B., et al. 174

Dougherty, G. G., Ellinwood, E. H.
The effect of reserpine on concurrent repeated administration of *d*-amphetamine 327

Dourish, C. T., see Greenshaw, A. J. 189

Dubini, A., see Cavagnini, F., et al. 157

Dudek, B. C., Abbott, M. E., Phillips, T. J.
Stimulant and depressant properties of sedative-hypnotics in mice selectively bred for differential sensitivity to ethanol 46

Durcan, M. J., Fulker, D. W., Campbell, I. C.
Differences in the stereotypy response but not the hypomotility response to apomorphine in the Roman High and Low Avoiding strains of rats 215

Dworkin, S. I., Guerin, G. F., Goeders, N. E., Cherek, D. R., Lane, J. D., Smith, J. E.
Reinforcer interactions under concurrent schedules of food, water, and intravenous morphine 282

Ebert, M. H., see Kraemer, G. W., et al. 266

Ellinwood, E. H., see Dougherty, G. G. 327

Estall, L. B., see Shephard, R. A. 343

Fagan, D., Scott, D. B., Tiplady, B.
A study of the effects of zimeldine on the pharmacokinetics and pharmacodynamics of temazepam in healthy volunteers 252

Fahn, S., see Reches, A., et al. 330

Fasmer, O. B., Berge, O.-G., Hole, K.
Metergoline elevates or reduces nociceptive thresholds in mice depending on test method and route of administration 306

Fechter, L. D., see Storm, J. E., et al. 68

Fekete, M., Tárczy, M., Bihari, K., Katona, G.
Dopamine/L-dopa ratio in cerebrospinal fluid of parkinsonian patients treated with L-dopa + benserazide 93

Fibiger, H. C., see Pittman, K. J., et al. 371

File, S. E., Green, A. R., Nutt, D. J., Vincent, N. D.
On the convulsant action of Ro 5-4864 and the existence of a micromolar benzodiazepine binding site in rat brain 199

File, S. E., Tucker, J. C.
Prenatal treatment with clomipramine: effects on the behaviour of male and female adolescent rats 221

Fisher, S., see Mansbridge, B. 225

Forloni, G. L., see Garattini, S., et al. 210

Fossati, R., see Cavagnini, F., et al. 157

Fredricson Overø, K., see Boeck, V., et al. 275

French, E. D., Vantini, G.
Phencyclidine-induced locomotor activity in the rat is blocked by 6-hydroxydopamine lesion of the nucleus accumbens: comparisons to other psychomotor stimulants 83

Fulker, D. W., see Durcan, M. J., et al. 215

Furukawa, T., see Ushijima, I., et al. 301

Gallaher, E. J., see Henauer, S. A., et al. 161

Garattini, S., Forloni, G. L., Tirelli, S., Ladinsky, H., Consolo, S.
Neurochemical effects of minaprine, a novel psychotropic drug, on the central cholinergic system of the rat 210

Garver, D. L., see Bennett, J. A., et al. 263

Gelfand, R., see White, K., et al. 258

Gerlach, J., Bjørndal, N., Christensson, E.
Methylphenidate, apomorphine, THIP, and diazepam in monkeys: Dopamine-GABA behavior related to psychoses and tardive dyskinesia 131

Gerhardt, S., see Neale, R., et al. 20

Ghoneim, M. M., Hinrichs, J. V., Mewaldt, S. P.
Dose-response analysis of the behavioral effects of diazepam: I. Learning and memory 291

Ghoneim, M. M., Mewaldt, S. P., Hinrichs, J. V.
Dose-response analysis of the behavioral effects of diazepam: II. Psychomotor performance, cognition and mood 296

Giknis, M. L. A., Damjanov, I.
Time interval between sequential exposures to ethanol is critical for the development of neural tolerance or sensitivity 229

Goeders, N. E., see Dworkin, S. I., et al. 282

Good, P. I., see Collins, R. J., et al. 6

Green, A. R., see File, S. E., et al. 199

Greenshaw, A. J., Dourish, C. T.
Differential aversive stimulus properties of β-phenylethylamine and of *d*-amphetamine 189

Griffiths, R. R., see Henningfield, J. E., et al. 1

Guaza, C., Borrell, S.
Effect of naloxone administration upon responses of adrenal hormones to withdrawal from ethanol 181

Guerin, G. F., see Dworkin, S. I., et al. 282

Gugath, M., see Laakmann, G., et al. 62

Haddox, V. G., see Menon, M. K., et al. 89

Hamano, H., see Miyachi, Y., et al. 287

Hamon, M., see Thiébot, M.-H., et al. 355

Harto-Truax, N. E., see Branconnier, R. J., et al. 256

Henauer, S. A., Gallaher, E. J., Hollister, L. E.
Long-lasting single-dose tolerance to neurologic deficits induced by diazepam 161

Henningfield, J. E., Chait, L. D., Griffiths, R. R.
Effects of ethanol on cigarette smoking by volunteers without histories of alcoholism 1

Hernandez, L., see Ahlskog, J. E., et al. 118

Hines, G., Poling, T. H.
Lithium effects on active and passive avoidance behavior in the rat 78

Hinrichs, J. V., see Ghoneim, M. M., et al. 291, 296

Hirschowitz, J., see Bennett, J. A., et al. 263

Hoaki, Y., see Nishikawa, T., et al. 153

Hoebel, B. G., see Ahlskog, J. E., et al. 118

Hole, K., see Fasmer, O. B., et al. 306

Hollister, L. E., see Henauer, S. A., et al. 161

Horita, A., see Lai, H. 335

Hutson, P. H., see Tricklebank, M. D., et al. 185

Huygens, P., see Introini, I. B., et al. 107

Introini, I. B., Baratti, C. M., Huygens, P.
Selective brain noradrenaline depletion induced by the neurotoxin N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP4) does not prevent the memory facilitation induced by a muscarinic agonist in mice 107
Iversen, S. D., see Mucha, R. F. 241

Jackson-Lewis, V., see Reches, A., et al. 330
Jadhav, J. H., see Balsara, J. J., et al. 237
Jakubovic, A., see Pittman, K. J., et al. 371
Jarvik, M. E., see Schneider, N. G. 143
Johanson, C. E., see Chait, L. D., et al. 272
Johnson, M., see Richelson, E. 27
Jørgensen, A., see Boeck, V., et al. 275
Jung, L., see Misslin, R., et al. 113
Jusko, W. J., see Sutfin, T. A., et al. 310

Katona, G., see Fekete, M., et al. 93
Koek, W., Slangen, J. L.
External stimulus control in a "drug-discrimination" procedure: Drug effects and inter-animal variation 168
Koga, I., see Nishikawa, T., et al. 153
Kraemer, G. W., Ebert, M. H., Lake, C. R., McKinney, W. T.
Hypersensitivity to *d*-amphetamine several years after early social deprivation in rhesus monkeys 266
Kucharski, L. T., Alexander, P., Tune, L., Coyle, J.
Serum neuroleptic concentrations and clinical response: A radioreceptor assay investigation of acutely psychotic patients 194
Kuribara, H., Tadokoro, S.
Conditioned lever-press avoidance response in mice: acquisition processes and effects of diazepam 36
Kuss, H.-J., see Laakmann, G., et al. 62

Laakmann, G., Gugath, M., Kuss, H.-J., Zygan, K.
Comparison of growth hormone and prolactin stimulation induced by chlorimipramine and desimipramine in man in connection with chlorimipramine metabolism 62
Ladinsky, H., see Garattini, S., et al. 210
Lai, H., Horita, A.
Apomorphine-induced hypothermia affected by acute treatment with apomorphine, haloperidol, or ethanol 335
Lake, C. R., see Kraemer, G. W., et al. 266
Lane, J. D., see Dworkin, S. I., et al. 282
Leshem, M.
Suppression of feeding by naloxone in rat: a dose-response comparison of anorexia and conditioned taste aversion suggesting a specific anorexic effect 127
Levitt, P., see Shaywitz, B. A., et al. 73
Lieblich, I., see Bergmann, F., et al. 248
Liebman, J. M., see Neale, R., et al. 20
Lindsay DeVane, C., see Sutfin, T. A., et al. 310
Lund, H., see Clemmesen, L., et al. 348

Magnusson, O., see Archer, T., et al. 14
Mansbridge, B., Fisher, S.
Public knowledge and attitudes about diazepam 225
Maraschini, C., see Cavagnini, F., et al. 157
Massari, V. J., see Bunney, W. C., et al. 318
McAllister, K. H., see Benton, D., et al. 41
McKinney, W. T., see Kraemer, G. W., et al. 266

Menon, M. K., Vivonia, C. A., Haddox, V. G.
Evidence for presynaptic antagonism by amantadine of indirectly acting central stimulants 89
Mewaldt, S. P., see Ghoneim, M. M., et al. 291, 296
Miglécz, E., see Székely, J. I., et al. 400
Mikkelsen, P. L., see Clemmesen, L., et al. 348
Millington, W. R., see Storm, J. E., et al. 68
Misslin, R., Ropartz, P., Jung, L.
Impairment of responses to novelty by apomorphine and its antagonism by neuroleptics in mice 113
Miyachi, Y., Mizuchi, A., Hamano, H., Sarai, K.
Effects of chronic sultopride treatment on endocrine systems in psychotic women 287
Mizuchi, A., see Miyachi, Y., et al. 287
Molloy, A. G., Waddington, J. L.
Dopaminergic behavior stereospecifically promoted by the D_1 agonist *R*-SK & F 38393 and selectively blocked by the D_1 antagonist SCH 23390 409
Morgan, K., Adam, K., Oswald, I.
Effects of loprazolam and of triazolam on psychological functions 386
Mucha, R. F., Iversen, S. D.
Reinforcing properties of morphine and naloxone revealed by conditioned place preferences: a procedural examination 241

Nandal, N. V., see Balsara, J. J., et al. 237
Naylor, R. J., see Costall, B., et al. 174
Neale, R., Gerhardt, S., Liebman, J. M.
Effects of dopamine agonists, catecholamine depletors, and cholinergic and GABAergic drugs on acute dyskinesias in squirrel monkeys 20
Nicholson, A. N., see Bradley, C. M. 395
Nielsen, E. B., Rolandi, W., Appel, J. B.
Drug effects on the repeated generalization of a visual discrimination acquired under one trial per day conditions 233
Nishikawa, T., Tsuda, A., Tanaka, M., Hoaki, Y., Koga, I., Uchida, Y.
Prophylactic effect of neuroleptics in symptom-free schizophrenics: A comparative dose-response study of haloperidol and propericiazine 153
Niven Thurman, D., see Bennett, J. A., et al. 263
Nutt, D. J., see File, S. E., et al. 199
Nwokeafor, V., see Shvartsburd, A., et al. 55

Ögren, S.-O., see Archer, T., et al. 14
Ögren, S. O., see Rönnbäck, L., et al. 30
Oliver, A. P., Parker, E. S., Wyatt, R. J.
Sequence of alcohol presentation is important in the potentiation of long-term events 52
Oswald, I., see Adam, K., et al. 389
Oswald, I., see Morgan, K., et al. 386
Overstreet, D. H., see Crocker, A. D. 102

Palmer, R., see White, K., et al. 258
Parker, E. S., see Oliver, A. P., et al. 52
Pert, A., see Bunney, W. C., et al. 318
Pevsner, J., see Sandberg, P. R., et al. 406
Phillips, T. J., see Dudek, B. C., et al. 46

Pittman, K. J., Jakubovic, A., Fibiger, H. C.
The effects of chronic lithium on behavioral and biochemical indices of dopamine receptor supersensitivity in the rat 371

Platt, J. E., see Stone, E. A., et al. 403

Poling, T. H., see Hines, G. 78

Porsolt, R. D.
Lack of tolerance to haloperidol-induced acute dyskinesias in rhesus monkeys 145

Precious, J. I., see Rodgers, R. J., et al. 322

Rafaelsen, O. J., see Clemmesen, L., et al. 348

Ramella, G., see Cavagnini, F., et al. 157

Randall, P. K., see Ahlskog, J. E., et al. 118

Razani, J., see White, K., et al. 258

Reches, A., Jackson-Lewis, V., Fahn, S.
Lithium does not interact with haloperidol in the dopaminergic pathways of the rat brain 330

Referees 412

Richards, C., see Rodgers, R. J., et al. 322

Richelson, E., Johnson, M.
Sodium-dependent lithium ion efflux from murine neuroblastoma and rat glioma cells: a minor pathway for efflux of lithium ions 27

Roberts, D. C. S., Vickers, G.
Atypical neuroleptics increase self-administration of cocaine: An evaluation of a behavioural screen for antipsychotic activity 135

Rodgers, R. J., Richards, C., Precious, J. I.
Naloxone administration following brief exposure to novelty reduces activity and rearing in mice upon 24-h retest: A conditioned aversion? 322

Romandini, S., Samanin, R.
Methysergide and metergoline reduce morphine analgesia with no effect on the development of tolerance in rats 140

Rönnbäck, L., Zeuchner, J., Rosengren, L., Wronski, A., Ögren, S. O.
Decreased morphine intake by opiate addicted rats administered zimelidine, a 5-HT uptake inhibitor 30

Rolandi, W., see Nielsen, E. B., et al. 233

Ropartz, P., see Misslin, R., et al. 113

Rosengren, L., see Rönnbäck, L., et al. 30

Ross, S. B., see Archer, T., et al. 14

Russel, R. R., see Collins, R. J., et al. 6

Samanin, R., see Romandini, S. 140

Sanberg, P. R., Pevsner, J., Coyle, J. T.
Parametric influences on catalepsy 406

Sarai, K., see Miyachi, Y., et al. 287

Sarne, Y., see Weizman, R., et al. 368

Schepers, G., see Deviche, P. 122

Schneider, N. G., Jarvik, M. E.
Time course of smoking withdrawal symptoms as a function of nicotine replacement 143

Scott, D. B., see Fagan, D., et al. 252

Shapiro, C., see Adam, K., et al. 389

Shaywitz, B. A., Teicher, M. H., Cohen, D. J., Anderson, G. M., Young, J. G., Levitt, P.
Dopaminergic but not noradrenergic mediation of hyperactivity and performance deficits in the developing rat pup 73

Shephard, R. A., Estall, L. B.
Anxiolytic actions of chlordiazepoxide determine its effects on hyponeophagia in rats 343

Shvartsburd, A., Nwokeafor, V., Smith, R. C.
Red blood cell and plasma levels of thioridazine and mesoridazine in schizophrenic patients 55

Simon, P., see Thiébot, M.-H., et al. 355

Simpson, G., see White, K., et al. 258

Slangen, J. L., see Koek, W. 168

Sloane, R. B., see White, K., et al. 258

Slucky, A. V., see Stone, E. A., et al. 403

Smith, J. E., see Dworkin, S. I., et al. 282

Smith, R. C., see Shvartsburd, A., et al. 55

Soubrié, P., see Thiébot, M.-H., et al. 355

Stone, E. A., Platt, J. E., Trullas, R., Slucky, A. V.
Reduction of the cAMP response to norepinephrine in rat cerebral cortex following repeated restraint stress 403

Storm, J. E., Millington, W. R., Fechter, L. D.
Diethyldithiocarbamate depresses the acoustic startle response in rats 68

Sutfin, T. A., Lindsay DeVane, C., Jusko, W. J.
The analysis and disposition of imipramine and its active metabolites in man 310

Székely, J. I., Miglécz, E., Bajusz, S.
Species differences in the relative analgesic potencies of some classical opiates and opioid peptides 400

Szekely, G., see Weizman, R., et al. 368

Tadokoro, S., see Kuribara, H. 36

Tanaka, M., see Nishikawa, T., et al. 153

Tárczy, M., see Fekete, M., et al. 93

Teicher, M. H., see Shaywitz, B. A., et al. 73

Thiébot, M.-H., Soubrié, P., Hamon, M., Simon, P.
Evidence against the involvement of serotonergic neurons in the anti-punishment activity of diazepam in the rat 355

Tiplady, B., see Fagan, D., et al. 252

Tirelli, S., see Garattini, S., et al. 210

Tricklebank, M. D., Hutson, P. H., Curzon, G.
Involvement of dopamine in the antinociceptive response to footshock 185

Trullas, R., see Stone, E. A., et al. 403

Tsuda, A., see Nishikawa, T., et al. 153

Tucker, J. C., see File, S. E. 221

Tune, L., see Kucharski, L. T., et al. 194

Tyano, S., see Weizman, A., et al. 382

Tyano, S., see Weizman, R., et al. 368

Uchida, Y., see Nishikawa, T., et al. 153

Uhlenhuth, E. H., see Chait, L. D., et al. 272

Ushijima, I., Yamada, K., Furukawa, T.
Acute and long-term effects of thyrotropin releasing hormone on behavior mediated by dopaminergic and cholinergic activities in mice 301

Vantini, G., see French, E. D. 83

Vickers, G., see Roberts, D. C. S. 135

Vincent, N. D., see File, S. E., et al. 199

Vivonia, C. A., see Menon, M. K., et al. 89

Waddington, J. L., see Molloy, A. G. 409

Warburton, D. M., see Wesnes, K. 147, 338

Weeks, J. R., see Collins, R. J., et al. 6

Weissman, B. A., see Weizman, R., et al. 368

Weizman, A., Tyano, S., Wijsenbeek, H., Ben David, M.
High dose diazepam treatment and its effect on prolactin secretion in adolescent schizophrenic patients 382

Weizman, A., see Weizman, R., et al. 368

Weizman, R., Weizman, A., Tyano, S., Szekely, G., Weissman, B. A., Sarne, Y.
Humoral-endorphin blood levels in autistic, schizophrenic and healthy subjects 368

Wesnes, K., Warburton, D. M.
Effects of scopolamine and nicotine on human rapid information processing performance 147

Wesnes, K., Warburton, D. M.
The effects of cigarettes of varying yield on rapid information processing performance **338**

White, J. M., see Williams, J. L. 360

White, K., Razani, J., Cadow, B., Gelfand, R., Palmer, R., Simpson, G., Sloane, R. B.
Tranylcypromine vs nortriptyline vs placebo in depressed outpatients: a controlled trial 258

White, N. M., see Carr, G. D. 203

Wijsenbeck, H., see Weizman, A., et al. 382

Williams, J. L., White, J. M.
The effects of amphetamine and scopolamine on adjunctive drinking and wheel-running in rats 360

Wronski, A., see Rönnbäck, L., et al. 30

Wyatt, R. J., see Oliver, A. P., et al. 52

Yamada, K., see Ushijima, I., et al. 301

Young, J. G., see Shaywitz, B. A., et al. 73

Zemlan, F., see Bennett, J. A., et al. 263

Zeuchner, J., see Rönnbäck, L., et al. 30

Zygan, K., see Laakmann, G., et al. 62

Indexed in Current Contents

Subject index

A
Abuse liability 6
Accidents 382
Acetaldehyde 46
Acetylcholine 20, 107, 210
Acetylcholinesterase 210
Active metabolites 310
Acute treatment 335
Adaption 406
Addiction 6
Adjunctive behavior 360
Adolescence 221
Adrenal catecholamine 181
Aging 256
Akathasia 95
Alcohol 46, 52
Alcoholics 1
Amantadine 89
Amitryptiline 256
Amphetamine 83, 89, 118, 203, 360, 371
Analgesia 140, 400
Angina 256
Anorexia 118, 122, 127
Anticholinergic effects 348
Antidepressant drugs 348
Antidepressants 275, 403
Antimuscarinic 256
Antipsychotic drugs 95, 368
Anxiety 14, 221, 343
Apomorphine 89, 113, 215, 237, 335, 371
Ataxia 161
Autism 368
Availability 310
Avoidance 36, 41, 78, 107

B
Baclofen 20
Benzodiazepine 199
Beta-Endorphin 400

C
Caffeine 83, 89
Catalepsy 102, 237, 406
Catecholamines 89, 118, 256
Cats 275
Caudate nucleus 203
Chlordiazepoxide 343
Chlorimipramine 62
Chlorpromazine 135, 168
Choice behavior 233
Cholinergic pathways 147
Chronotropy, positiv 256
Cigarettes 1
Circadian influences 291
Citalopram 275
Clozapine 135
Cocaine 89
Cocaine self-administration 135
Cognition 296
Consolidation 107
Convulsions 199
Coordination 46
Corticosterone 181

D
d-Amphetamine 189, 266, 272
DA receptors 371
Dependence, physical 6
Desimipramine 62, 263, 310
Dextroamphetamine 327
Development 221
Diabetes 248
Diazepam 20, 30, 161, 225, 291, 296, 355, 382
Discrimination 233
Disinhibition 395
Disorders, manic 78
Dopamine 20, 73, 93, 102, 107, 174, 185, 215, 330, 371, 409
Dose response 127, 282, 296
Drinking 122, 360
Drug discrimination 168, 272
Drug effects 1
Drug interactions 252
Drug knowledge 225
Dyskinesia 20

E
Eating 127
Encephalin analogues 400
Endorphine 378
Exploration 113
Exploration habituation 221
Ethanol 1, 181, 229, 335
Extinction 41, 282

F
Feeding 118, 122, 343
Fenfluramine 14, 118
Fear retension 14
First pass metabolism 310
Flupenthixol 135
Flurazepam 395
Food intake 41, 282
Food tremor 95

G
Genetics 215
Guinea pig 52
Grooming 409
Growth hormone 62

H
Haloperidol 102, 135, 153, 168, 237, 330, 335, 406
Hamilton depression scale 263
Hippocampus 52, 210
Hot plate test 306

Humans 1, 55, 62, 93, 95, 147, 153, 194, 225, 252, 256, 263, 272, 287, 291, 296, 310, 338, 348, 368, 382, 386, 389
5-Hydroxytryptamine 305
Hyperactivity 73
Hyperthyroid 102
Hypomotility 215
Hyponeophagia 343
Hypothermia 335
Hypothyroid 102

I
Imipramine 310
Imipramine-N-oxide 348
Ingestion 30
Intracerebral infusion 174
Isocarboxide 348

K
Key peck 233
Kindling 52

L
Learning 291
Lesions 318
Levorphanol 89
Lithium 78, 330, 348, 371
Lithium ions 27
Locomotion 46, 83, 102, 113, 318
Locomotor activity 174
Long term effect 301
Loprazolam 386, 389

M
Memantine 89
Memory 52, 107, 291, 322
Memory facilitation 203
Mesoridazine 55
Metergoline 140, 306
Methadone 378
Methamphetamine 113, 237
Methylphenidate 89
Metoclopramide 135
Mianserin 348
Mice 36, 41, 46, 89, 107, 113, 161, 199, 299, 301, 322, 378, 400
Minaprine 210
Monkey 6, 20, 145, 266, 395
Monoamines 210
Mood 296
Morphine 30, 168, 233, 318, 378, 400
Morphine self-administration 282
Morphine tolerance 140, 248
Motor activity 89
Multiple reinforcers 282

N
Naloxone 41, 122, 127, 181, 237, 322
Neural sensitivity 229
Neurotransmitter substances 174
Nociception 140, 306
Nicotine 147, 338
Nomifensine 348
Noradrenaline 107, 389
Norepinephrine 68, 73, 256, 266, 403
Nortriptyline 348
Novelty 322
Novelty preference 113
Nucleus accumbens 83, 174, 318

O
Obesity 118
Opiates 122, 378, 400
Opiate delta receptor 41
Opioids 322
Oxotremorine 107

P
Phencyclidine 83
Pain threshold 248
Parkinson's disease 93
Pentobarbital 46
Performance 296, 338
Performance, psychomotor 252
Pharmacodynamics 252
Pharmacogenetics 46
Pharmacokinetics 252, 310
Pharmacology, behavioral 1
Phencyclidine 89
Picrotoxin 199
Pigeon 122, 233
Pimozide 135
Place aversion 322
Plasma level 275
Prenatal treatment 221
Prolactin 62, 153, 382
Psychometrics 1
Psychosis 194

R
Rabbits 275
Rapid information processing 338
Rat 6, 14, 27, 30, 68, 73, 78, 102, 118, 127, 135, 140, 168, 174, 181, 185, 189, 199, 203, 210, 215, 221, 237, 248« 318, 327, 330, 335, 343, 355, 360, 371, 400, 403, 406, 409
Rebound 389
Rebound insomnia 386
Recovery 291
Red blood cells 55
Reinforcement 6
Reserpine 327
Rotarod test 161

S
Saccharin intake 248
Safety margins 275
Salivation 348
Schizophrenia 55, 153, 266, 368, 382
Scopolamine 83, 147, 168, 360
Self-administration 6
Serotonin 107, 355
Serum levels 194
Sinus heart rate 256
6-Hydroxydopamine 73
Sleep 229, 389
Smoking 1, 338
Social interaction 221
Sodium-dependent lithium efflux 27
Startle reflex 62
Stereotypy 189, 203, 215, 237, 301, 327, 409
Stimulant abuse 89
Stimulus control 168
Streptozotocin 248
Stress 181, 185, 378, 403
Striatum 210
Substantia nigra 355
Sulpiride 135

T
Tail flick test 306
Taste aversion 127, 189, 322
Temazepam 252
Thioridazine 55, 135, 263
Thyrotropin releasing hormone 310
Thyroxine 102
Tolerance 229, 389
Tremor 301
Triazolam 386, 389

V
Valium 225

W
Water intake 282
Wheel-running 360
Withdrawal 181, 378

X
Xerostomia 348

Z
Zimelidine 30, 252, 348